4th interim analysis of PEARL study shows treatment pauses with CGRP mAbs like fremanezumab may increase monthly migraine days and reduce effectiveness.
4th interim analysis of PEARL migraine prevention study with AJOVY (fremanezumab) reveals that treatment pauses with CGRP mAbs, such as fremanezumab, may lead to an increase in monthly migraine days and reduced effectiveness upon reinitiation. These findings challenge the rationale for treatment interruptions recommended or mandated by some reimbursement authorities after one year of continuous use.
June 28, 2024
3 Articles